看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -1.7x - -1.9x | -1.8x |
| Historical Pb Multiple | -16.9x - 39.1x | -3.4x |
| Fair Value | $3.88 - $4.28 | $4.08 |
| Upside | -50.4% - -45.2% | -47.8% |
| Benchmarks | - | Full Ticker |
| Intellia Therapeutics, Inc. | - | NasdaqGM:NTLA |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Ionis Pharmaceuticals, Inc. | - | NasdaqGS:IONS |
| KalVista Pharmaceuticals, Inc. | - | NasdaqGM:KALV |
| CSL Limited | - | OTCPK:CMXH.F |
| BioCryst Pharmaceuticals, Inc. | - | NasdaqGS:BCRX |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| NTLA | BMRN | IONS | KALV | CMXH.F | BCRX | |||
| NasdaqGM:NTLA | NasdaqGS:BMRN | NasdaqGS:IONS | NasdaqGM:KALV | OTCPK:CMXH.F | NasdaqGS:BCRX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 6.6% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | 3.6% | NM- | ||
| Latest Twelve Months | -7.9% | 154.6% | -23.9% | -62.4% | 11.2% | 60.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -746.7% | 13.5% | -37.4% | -564.2% | 20.7% | -190.2% | ||
| Prior Fiscal Year | -1326.5% | 6.9% | -46.5% | NA | 16.5% | -68.4% | ||
| Latest Fiscal Year | -896.8% | 15.0% | -64.4% | NA | 17.9% | -19.7% | ||
| Latest Twelve Months | -896.8% | 15.0% | -64.4% | NA | 18.0% | -19.7% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -43.6% | 7.0% | -43.8% | -60.4% | 21.9% | -2325.6% | ||
| Prior Fiscal Year | -42.1% | 3.5% | -76.3% | -53.7% | 14.5% | NM | ||
| Latest Twelve Months | -54.0% | 8.0% | -93.1% | -150.5% | 15.4% | NM | ||
| Next Fiscal Year | -77.7% | 14.1% | -140.5% | -144.8% | 17.3% | 2.4% | ||
| Two Fiscal Years Forward | -373.1% | 15.4% | 527.0% | 359.0% | 17.6% | -15.0% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 14.9x | 4.1x | 6.5x | NA | 4.8x | 3.6x | ||
| Price / LTM EPS | -1.7x | 27.6x | -10.2x | -3.5x | 26.8x | -18.4x | ||
| Price / Book | 1.0x | 2.1x | 7.8x | 4.2x | 4.0x | -3.4x | ||
| Price / Fwd Book | 2.2x | 1.8x | 44.9x | 18.5x | 3.9x | -3.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.0x | 4.0x | 7.8x | |||||
| Historical P/B Ratio | -16.9x | -3.4x | 39.1x | |||||
| Selected P/B Multiple | -1.7x | -1.8x | -1.9x | |||||
| (x) Book Value | (476) | (476) | (476) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | NTLA | BMRN | IONS | KALV | CMXH.F | BCRX | |
| Value of Common Equity | 860 | 11,793 | 4,615 | 612 | 74,251 | 1,634 | |
| (/) Shares Outstanding | 103.5 | 191.8 | 159.0 | 49.7 | 484.2 | 209.0 | |
| Implied Stock Price | 8.31 | 61.50 | 29.03 | 12.30 | 153.34 | 7.82 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8.31 | 61.50 | 29.03 | 12.30 | 153.34 | 7.82 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |